Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis

By sjmartinez • October 28, 2022

Swain SM, Macharia H, Cortes J, Dang C, Gianni L, Hurvitz SA, Jackisch C, Schneeweiss A, Slamon D, Valagussa P, du Toit Y, Heinzmann D, Knott A, Song C, Cortazar P. Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis. Cancers (Basel). 2022 Oct 15;14(20):5051. doi: 10.3390/cancers14205051. PMID: 36291835.

Tags: dual HER2 targeting, early breast cancer, event-free survival, Hematology/Oncology, HER2, pathologic complete response, pertuzumab, Publications, trastuzumab

Related Posts

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival

Crown J, Stroyakovskii D, Yardley DA, Huang CS, Fasching PA, Bardia A, Chia S, Im SA, Martin M, Xu B, Barrios CH, Untch M, Moroose[...]

Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy

Wang Y, Guan Y, Abbas AR, Sano Y, Jain S, Lu S, Hamidi H, Koeppen H, Azuma Y, Kayukawa Y, Shinozuka J, Pochiraju A, Webster[...]

Tumor Extracellular Vesicle Digital Scoring Assays for Cancer Detection and Monitoring

Lee J, Zhao C, Yang J, Jonas SJ, Agopian V, You S, Posadas E, Yang JD, Zhu Y, Tseng HR. Tumor Extracellular Vesicle Digital Scoring[...]